Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | FLT3 exon 14 ins |
| Therapy | Narazaciclib |
| Indication/Tumor Type | acute myeloid leukemia |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| FLT3 exon 14 ins | acute myeloid leukemia | sensitive | Narazaciclib | Preclinical - Pdx & cell culture | Actionable | In a preclinical study, Narazaciclib (ON123300) inhibited proliferation of acute myeloid leukemia cell lines harboring FLT3-ITD in culture, and decreased tumor burden in a cell line xenograft model and a patient-derived xenograft (PDX) model (PMID: 38641704). | 38641704 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (38641704) | Narazaciclib, a novel multi-kinase inhibitor with potent activity against CSF1R, FLT3 and CDK6, shows strong anti-AML activity in defined preclinical models. | Full reference... |